Le Lézard
Classified in: Health
Subject: SVY

Neurology Markets for Transdermal Patches


LONDON, Oct. 18, 2017 /PRNewswire/ -- Unlike several other disease segments, progress toward curative medicine for neurological and related central nervous system disorders has remained elusive.

Download the full report: https://www.reportbuyer.com/product/5151449



The result is a therapeutic segment that relies heavily on control of symptoms and palliative care. These trends include the growing incidence of neurological disorders associated with longevity and aging, and significant increases in the number of children diagnosed with autism.

Because diseases of the central nervous system often result in compromised cognitive and/or motor skills that can increase the level of involuntary non-compliance with therapeutic protocols, transdermal delivery of drugs targeting CNS disorders is generally viewed as a method that can increase patient safety and improve outcomes.

In addition to the handful of FDA-approved transdermal CNS products, more than a dozen companies are currently pursuing a range of APIs in transdermal delivery systems that target neurological and CNS conditions. While none of these development-stage candidates is curative, the benefits they can offer in terms of patient ease-of-use, product safety and overall quality-of-care are expected to result in reduced morbidity and more effective symptom management for afflicted patients

Neurology Markets for Transdermal Patches ? What You Will Learn
- Analyzes and evaluates the global market opportunity for transdermal neurology prescription therapeutics and assesses the probable impact of evolving regulatory, economic and demand factors
- Assesses transdermal products approved or in development for the delivery of therapeutic neurology drugs
- Provides detailed descriptions of neurology treatment segments, market factors, and business strategies
- Forecasts transdermal neurology drug product demand to 2022 by geographic region and product segment
- Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners
- Evaluates the impact of economic, technology, and regulatory factors on CNS therapeutics demand

Download the full report: https://www.reportbuyer.com/product/5151449

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 00:39
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...

25 avr 2024
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...

25 avr 2024
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

25 avr 2024
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

25 avr 2024
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...



News published on and distributed by: